Developing new antibiotic treatments, promoting responsible use, and ensuring access for all
The Global Antibiotic Research and Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). The mission of this not-for-profit research and development (R&D) initiative is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need.
The Role of WHO
WHO provides support in setting priorities and target product profiles, leads the Global Development and Stewardship Framework for AMR, garners Member State support and ensures effective liaison with relevant WHO departments.
The Role of DNDi
DNDi provides the governance, scientific environment and input and infrastructure, as well as the support for resource mobilization, communication, finance, and human resources necessary to build and launch solid R&D programmes.
Governance & Team
The GARDP team is led by its Director, who also serves as a member of DNDi‘s Executive Team. DNDi‘s Board of Directors oversee GARDP’s activities, with expert advice from the GARDP Scientific Advisory Committee.
A partnership model for product development, based on the experience gained from the field of neglected diseases, can provide an important element of the overall strategy for R&D in the field of antibiotics. Such a partnership can test new incentives that also contribute to conservation of and access to new antibiotic treatments. By doing so, it can provide an important alternative to the traditional market-driven pharmaceutical approach, by focusing on products that the pharmaceutical industry will likely not develop for lack of profitability.
GARDP works closely with all stakeholders in the field of antibiotic R&D – including pharmaceutical and biotechnology companies, startups, other product development partnerships, academia, civil society, and health authorities – from countries of all income levels – to develop new antibiotic treatments.
- addresses global public health and specific needs of low- and middle-income countries;
- targets products that industry will likely not develop due to lack of profitability or other reasons;
- pilots the use of alternative incentive models delinking cost of R&D from volume-based sales and prices of antibiotics, which support conservation of and access to new antibiotics; and
- ensures that new antibiotics developed by GARDP are affordable to all in need.
To ensure that GARDP focuses its scientific portfolio towards meeting priority needs, its R&D prioritization process begins with the requirement that any programme meets at least two out of three key criteria:
1. Target priority pathogens
2. Address priority diseases and syndromes
3. Help under-served priority patient populations
GARDP’s objectives: 2017-2023
- Develop and deliver up to four new treatments through improvement of existing antibiotics and acceleration of the entry of new chemical entities. Build a robust pipeline of pre-clinical and clinical candidates with up to four candidates brought into pre-clinical or clinical development.
- Secure EUR 270 million to execute its R&D programmes, build a highly experienced R&D team, and establish a dedicated entity.
- Support and advocate for appropriate use of antibiotics, sustainable access, and suitable financing of R&D for new antibiotic treatments.
GARDP has launched programmes on Neonatal Sepsis, Sexually Transmitted Infections (STIs) and the Antimicrobial Memory Recovery Initiative (AMRI) and a fourth programme is currently in development. Visit the GARDP website
While significant achievements have been made in reducing mortality in children under the age of five, mortality remains a burden in children less than one month of age with antimicrobial resistance posing a particular threat. Read more
This programme aims to optimize current treatments and accelerate development of pipeline/ new antibiotics for children through improvements in dose, duration of treatment, and formulation, or through combinations.
A significant sexually transmitted infection (STI), Neisseria gonorrhoeae is threatening to soon become untreatable due to its resistance to all available classes of antimicrobials. This programme will accelerate the entry of new antibiotics and explore the use of combinations. Read more
Through this early-stage programme, GARDP will explore and support alternative upstream R&D approaches to address gram-negative pathogens that cause serious bacterial infections as well as possibly fungal infections. Read more about AMRI